Zhu et al studied the combination of Flt3 TKIs (Gilteritinib or Sorafenib) with BCL-2 selective inhibitor (BCL-2i) that synergistically enhanced apoptosis and reduced cell proliferation in Flt3/ITD cell lines and primary AML samples.5 The gene discussed is FLT3; the disease is acute myeloid leukemia.